Phosphatase inhibitors function as novel, broad spectrum Botulinum neurotoxin antagonists in mouse and human embryonic stem cell-derived motor neuron-based assays

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Kiris, Erkan ^a,b,c   Nuss, Jonathan E ^b   Stanford, Stephanie M ^d   Wanner, Laura M ^b   Cazares, Lisa ^b   Maestre, Michael F ^d   Du, Hao T ^b   Gomba, Glenn Y ^b   Burnett, James C ^e,f   Gussio, Rick ^f   Bottini, Nunzio ^d   Panchal, Rekha G ^b   Kane, Christopher D ^b,g,h   Tessarollo, Lino ^c   Bavari, Sina ^b  

^a Geneva Foundation   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^h U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BVT 948; ESTERASE INHIBITOR; MV 150; NEUROPROTECTIVE AGENT; NSC 663284; PENTAMIDINE; PHENANTHRENEQUINONE; SNARE PROTEIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MOLECULAR LIBRARY; PHOSPHATASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOTONEURON; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN CLEAVAGE; STEM CELL CULTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY;

ANIMALS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EMBRYONIC STEM CELLS; ENZYME INHIBITORS; HUMANS; MICE; MOTOR NEURONS; PHOSPHORIC MONOESTER HYDROLASES; SMALL MOLECULE LIBRARIES; SNARE PROTEINS;

EID: 84936976934     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129264     Document Type: Article

References (88)

1. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature reviews Microbiology. 2014; 12(8):535-49. doi: 10.1038/nrmicro3295 PMID: 24975322
2. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 2012; 4(10):913-39. doi: 10.3390/toxins4100913 PMID: 23162705
3. American Society of Plastic Surgeons. 2013 Plastic Surgery Statistics Report. Available at http://www.plasticsurgery.org/news/plastic-surgery-statistics/2013.html Accessed May 19, 2014.
4. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A. 2005; 102(28):9984-9. PMID: 15985558
5. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001; 285(8):1059-70. PMID: 11209178
6. FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. (Accessed July 29, 2013).
7. Larsen JC. U.S. Army Botulinum Neurotoxin (BoNT) Medical Therapeutics Research Program: Past Accomplishments and Future Directions. Drug Dev Res. 2009;(70:) :266-78.
8. Sheth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis. 2008; 47 (10):1245-51. doi: 10.1086/592574 PMID: 18834318
9. Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2011; 16(1):202-20. doi: 10.3390/molecules16010202 PMID: 21193845
10. Kiris E, Burnett JC, Kane CD, Bavari S. Recent Advances in Botulinum Neurotoxin Inhibitor Development. Curr Top Med Chem. 2014; 14(18):2044-61. PMID: 25335887
11. Opsenica I, Filipovic V, Nuss JE, Gomba LM, Opsenica D, Burnett JC, et al. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease. Eur J Med Chem. 2012; 53:374-9. doi: 10.1016/j.ejmech.2012.03.043 PMID: 22516424
12. Opsenica IM, Tot M, Gomba L, Nuss JE, Sciotti RJ, Bavari S, et al. 4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity. J Med Chem. 2013; 56(14):5860-71. doi: 10.1021/jm4006077 PMID: 23815186
13. Videnovic M, Opsenica DM, Burnett JC, Gomba L, Nuss JE, Selakovic Z, et al. Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria. J Med Chem. 2014; 57(10):4134-53. doi: 10.1021/jm500033r PMID: 24742203
14. Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, et al. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorg Med Chem. 2011; 19(24):7338-48. doi: 10.1016/j.bmc.2011.10.062 PMID: 22082667
15. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis. 2004; 10(9):1606-11. PMID: 15498163
16. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010; 79:591-617. doi: 10.1146/annurev.biochem.051908.125345 PMID: 20233039
17. Tighe AP, Schiavo G. Botulinum neurotoxins: Mechanism of action. Toxicon. 2012.
18. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999; 96(6):3200-5. PMID: 10077661
19. Coffield JA, Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther. 2009; 330(1):352-8. doi: 10.1124/jpet.108.147744 PMID: 19372387
20. Ibanez C, Blanes-Mira C, Fernandez-Ballester G, Planells-Cases R, Ferrer-Montiel A. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett. 2004; 578(1-2):121-7.
21. Blanes-Mira C, Ibanez C, Fernandez-Ballester G, Planells-Cases R, Perez-Paya E, Ferrer-Montiel A. Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue. Biochemistry. 2001; 40(7):2234-42. PMID: 11329292
22. Encinar JA, Fernandez A, Ferragut JA, Gonzalez-Ros JM, DasGupta BR, Montal M, et al. Structural stabilization of botulinum neurotoxins by tyrosine phosphorylation. FEBS Lett. 1998; 429(1):78-82. PMID: 9657387
23. Ferrer-Montiel AV, Canaves JM, DasGupta BR, Wilson MC, Montal M. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem. 1996; 271(31):18322-5. PMID: 8702470
24. Toth S, Brueggmann EE, Oyler GA, Smith LA, Hines HB, Ahmed SA. Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol. 2012; 3:102. doi: 10.3389/fphar.2012.00102 PMID: 22675300
25. Kiris E, Burnett JC, Nuss JE, Wanner LM, Peyser BD, Du HT, et al. Src Family Kinase Inhibitors Antagonize the Toxicity of Multiple Serotypes of Botulinum Neurotoxin in Human Embryonic Stem Cell-Derived Motor Neurons. Neurotox Res. 2015;Online First: doi: 10.1007/s12640-015-9526-z
26. De Munter S, Kohn M, Bollen M. Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem Biol. 2013; 8(1):36-45. doi: 10.1021/cb300597g PMID: 23214403
27. Kiris E, Kota KP, Burnett JC, Soloveva V, Kane CD, Bavari S. Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn. 2014; 14(2):153-68. doi: 10.1586/14737159.2014.867808 PMID: 24450833
28. Wichterle H, Peljto M. Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr Protoc Stem Cell Biol. 2008;Chapter 1:Unit 1H -H 9.
29. Amoroso MW, Croft GF, Williams DJ, O'Keeffe S, Carrasco MA, Davis AR, et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci. 2013; 33(2):574-86. doi: 10.1523/JNEUROSCI.0906-12.2013 PMID: 23303937
30. Kiris E, Nuss JE, Burnett JC, Kota KP, Koh DC, Wanner LM, et al. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res. 2011; 6(3):195-205. doi: 10.1016/j.scr.2011.01.002 PMID: 21353660
31. Li XJ, Hu BY, Jones SA, Zhang YS, Lavaute T, Du ZW, et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells. 2008; 26(4):886-93. doi: 10.1634/stemcells.2007-0620 PMID: 18238853
32. Hu BY, Zhang SC. Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. Methods Mol Biol. 2009; 636:123-37.
33. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G, et al. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells. 2007; 25 (8):1931-9. PMID: 17478583
34. Nuss JE, Ruthel G, Tressler LE, Wanner LM, Torres-Melendez E, Hale ML, et al. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J Biomol Screen. 2010; 15(1):42-51. doi: 10.1177/1087057109354779 PMID: 19965805
35. Kota KP, Soloveva V, Wanner LM, Gomba G, Kiris E, Panchal RG, et al. A high content imaging assay for identification of botulinum neurotoxin inhibitors. J Vis Exp. 2014;(93:) :e51915. doi: 10.3791/51915 PMID: 25489815
36. Huang PP, Khan I, Suhail MS, Malkmus S, Yaksh TL. Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS One. 2011; 6(4):e19126. doi: 10.1371/journal.pone.0019126 PMID: 21559464
37. Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007; 581 (25):4803-8. PMID: 17889852
38. Nuss JE, Wanner LM, Tressler LE, Bavari S. The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity. J Biomol Screen. 2010; 15(8):928-36. doi: 10.1177/1087057110374996 PMID: 20720092
39. Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999; 456(1):137-42. PMID: 10452545
40. Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon. 2013; 67:87-93. doi: 10.1016/j.toxicon.2012.11.011 PMID: 23201505
41. Kalandakanond S, Coffield JA. Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. J Pharmacol Exp Ther. 2001; 296(3):749-55. PMID: 11181902
42. Apland JP, Adler M, Oyler GA. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25. J Protein Chem. 2003; 22(2):147-53. PMID: 12760419
43. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365(6442):160-3. PMID: 8103915
44. Apland JP, Biser JA, Adler M, Ferrer-Montiel AV, Montal M, Canaves JM, et al. Peptides that mimic the carboxy-terminal domain of SNAP-25 block acetylcholine release at an Aplysia synapse. J Appl Toxicol. 1999; 19 Suppl 1:S23-6. PMID: 10594895
45. Bajohrs M, Rickman C, Binz T, Davletov B. A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO reports. 2004; 5(11):1090-5. PMID: 15486565
46. Keller JE, Neale EA. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J Biol Chem. 2001; 276(16):13476-82. PMID: 11278807
47. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005; 5 (3):274-9. PMID: 15907915
48. Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature. 2004; 432(7019):925-9. PMID: 15592454
49. Brunger AT, Jin R, Breidenbach MA. Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell Mol Life Sci. 2008; 65(15):2296-306. doi: 10.1007/s00018-008-8088-0 PMID: 18425411
50. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002; 1(14):1255-64. PMID: 12516958
51. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007; 7(7):495-507. PMID: 17568790
52. Liljebris C, Baranczewski P, Bjorkstrand E, Bystrom S, Lundgren B, Tjernberg A, et al. Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione. J Pharmacol Exp Ther. 2004; 309(2):711-9. PMID: 14747616
53. Wang Q, Dube D, Friesen RW, LeRiche TG, Bateman KP, Trimble L, et al. Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry. 2004; 43(14):4294-303. PMID: 15065873
54. Panchal RG, Ulrich RL, Bradfute SB, Lane D, Ruthel G, Kenny TA, et al. Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis. J Biol Chem. 2009; 284(19):12874-85. doi: 10.1074/jbc.M809633200 PMID: 19269962
55. Urbanek RA, Suchard SJ, Steelman GB, Knappenberger KS, Sygowski LA, Veale CA, et al. Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J Med Chem. 2001; 44(11):1777-93. PMID: 11356112
56. Hakami RM, Ruthel G, Stahl AM, Bavari S. Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol. 2010; 18(4):164-72. doi: 10.1016/j.tim.2010.02.001 PMID: 20202845
57. Pellett S, Du ZW, Pier CL, Tepp WH, Zhang SC, Johnson EA. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem Biophys Res Commun. 2011; 404(1):388-92. doi: 10.1016/j.bbrc.2010.11.128 PMID: 21130748
58. McNutt P, Celver J, Hamilton T, Mesngon M. Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem Biophys Res Commun. 2011; 405 (1):85-90. doi: 10.1016/j.bbrc.2010.12.132 PMID: 21215258
59. Gao J, Takeuchi H, Zhang Z, Fukuda M, Hirata M. Phospholipase C-related but catalytically inactive protein (PRIP) modulates synaptosomal-associated protein 25 (SNAP-25) phosphorylation and exocytosis. J Biol Chem. 2012; 287(13):10565-78. doi: 10.1074/jbc.M111.294645 PMID: 22311984
60. Shu Y, Liu X, Yang Y, Takahashi M, Gillis KD. Phosphorylation of SNAP-25 at Ser187 mediates enhancement of exocytosis by a phorbol ester in INS-1 cells. J Neurosci. 2008; 28(1):21-30. doi: 10.1523/JNEUROSCI.2352-07.2008 PMID: 18171919
61. Hepp R, Cabaniols JP, Roche PA. Differential phosphorylation of SNAP-25 in vivo by protein kinase C and protein kinase A. FEBS Lett. 2002; 532(1-2):52-6.
62. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A. 2009; 106(5):1330-5. doi: 10.1073/pnas.0812839106 PMID: 19164566
63. Fischer A. Synchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons. Curr Top Microbiol Immunol. 2013; 364:115-37. doi: 10.1007/978-3-642-33570-9-6 PMID: 23239351
64. Dolly JO, Lawrence GW, Meng J, Wang J, Ovsepian SV. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol. 2009; 9(3):326-35. doi: 10.1016/j.coph.2009.03.004 PMID: 19394272
65. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312(5773):592-6. PMID: 16543415
66. Sun S, Tepp WH, Johnson EA, Chapman ER. Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH. Biochemistry. 2012; 51(28):5655-62. PMID: 22720883
67. Chatterjee J, Kohn M. Targeting the untargetable: recent advances in the selective chemical modulation of protein phosphatase-1 activity. Curr Opin Chem Biol. 2013; 17(3):361-8. doi: 10.1016/j.cbpa.2013.04.008 PMID: 23647984
68. Tsaytler P, Harding HP, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011; 332(6025):91-4. doi: 10.1126/science.1201396 PMID: 21385720
69. McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol. 2009; 75(6):1249-61. doi: 10.1124/mol.108.053140 PMID: 19299564
70. Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001; 44(24):4042-9. PMID: 11708908
71. Zhang Y, Qu D, Morris EJ, O'Hare MJ, Callaghan SM, Slack RS, et al. The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin. J Neurosci. 2006; 26(34):8819-28. PMID: 16928871
72. Dumaual CM, Sandusky GE, Crowell PL, Randall SK. Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. J Histochem Cytochem. 2006; 54(12):1401-12. PMID: 16957164
73. Takano S, Fukuyama H, Fukumoto M, Kimura J, Xue JH, Ohashi H, et al. PRL-1, a protein tyrosine phosphatase, is expressed in neurons and oligodendrocytes in the brain and induced in the cerebral cortex following transient forebrain ischemia. Brain Res Mol Brain Res. 1996; 40(1):105-15. PMID: 8840018
74. Rios P, Li X, Kohn M. Molecular mechanisms of the PRL phosphatases. The FEBS journal. 2013; 280 (2):505-24. doi: 10.1111/j.1742-4658.2012.08565.x PMID: 22413991
75. Reynolds IJ, Aizenman E. Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. J Neurosci. 1992; 12(3):970-5. PMID: 1532027
76. Ozek C, Kanoski SE, Zhang ZY, Grill HJ, Bence KK. Protein-tyrosine Phosphatase 1B (PTP1B) Is a Novel Regulator of Central Brain-derived Neurotrophic Factor and Tropomyosin Receptor Kinase B (TrkB) Signaling. J Biol Chem. 2014; 289(46):31682-92. doi: 10.1074/jbc.M114.603621 PMID: 25288805
77. Fuentes F, Zimmer D, Atienza M, Schottenfeld J, Penkala I, Bale T, et al. Protein tyrosine phosphatase PTP1B is involved in hippocampal synapse formation and learning. PLoS One. 2012; 7(7):e41536. doi: 10.1371/journal.pone.0041536 PMID: 22844492
78. Nagy G, Reim K, Matti U, Brose N, Binz T, Rettig J, et al. Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. Neuron. 2004; 41(3):417-29. PMID: 14766180
79. Risinger C, Bennett MK. Differential phosphorylation of syntaxin and synaptosome-associated protein of 25 kDa (SNAP-25) isoforms. J Neurochem. 1999; 72(2):614-24. PMID: 9930733
80. Nagy G, Matti U, Nehring RB, Binz T, Rettig J, Neher E, et al. Protein kinase C-dependent phosphorylation of synaptosome-associated protein of 25 kDa at Ser187 potentiates vesicle recruitment. J Neurosci. 2002; 22(21):9278-86. PMID: 12417653
81. Shimazaki Y, Nishiki T, Omori A, Sekiguchi M, Kamata Y, Kozaki S, et al. Phosphorylation of 25-kDa synaptosome-associated protein. Possible involvement in protein kinase C-mediated regulation of neurotransmitter release. J Biol Chem. 1996; 271(24):14548-53. PMID: 8662851
82. Foletti DL, Lin R, Finley MA, Scheller RH. Phosphorylated syntaxin 1 is localized to discrete domains along a subset of axons. J Neurosci. 2000; 20(12):4535-44. PMID: 10844023
83. Lau CG, Takayasu Y, Rodenas-Ruano A, Paternain AV, Lerma J, Bennett MV, et al. SNAP-25 is a target of protein kinase C phosphorylation critical to NMDA receptor trafficking. J Neurosci. 2010; 30 (1):242-54. doi: 10.1523/JNEUROSCI.4933-08.2010 PMID: 20053906
84. Snyder DA, Kelly ML, Woodbury DJ. SNARE complex regulation by phosphorylation. Cell Biochem Biophys. 2006; 45(1):111-23. PMID: 16679567
85. Yang Y, Craig TJ, Chen X, Ciufo LF, Takahashi M, Morgan A, et al. Phosphomimetic mutation of Ser-187 of SNAP-25 increases both syntaxin binding and highly Ca2+-sensitive exocytosis. J Gen Physiol. 2007; 129(3):233-44. PMID: 17325194
86. Takahashi M, Itakura M, Kataoka M. New aspects of neurotransmitter release and exocytosis: regulation of neurotransmitter release by phosphorylation. J Pharmacol Sci. 2003; 93(1):41-5. PMID: 14501150
87. Kataoka M, Kuwahara R, Iwasaki S, Shoji-Kasai Y, Takahashi M. Nerve growth factor-induced phosphorylation of SNAP-25 in PC12 cells: a possible involvement in the regulation of SNAP-25 localization. J Neurochem. 2000; 74(5):2058-66. PMID: 10800949
88. Iida Y, Yamamori S, Itakura M, Miyaoka H, Takahashi M. Protein phosphatase 2A dephosphorylates SNAP-25 through two distinct mechanisms in mouse brain synaptosomes. Neurosci Res. 2013; 75 (3):184-9. doi: 10.1016/j.neures.2013.01.002 PMID: 23376809